ກ່ຽວກັບ Assertio Therapeutics, Inc.
Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As of 2019, Assertio markets three products approved by the FDA: Gralise, Cambia, and Zipsor.
Source: Wikipedia
ສຳນັກງານໃຫຍ່251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US
ກໍ່ຕັ້ງ2018
ສະຖານະໃຊ້ງານຢູ່
ສິດທິບັດ1 ສິດທິບັດ
GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF CNS DISORDERSEP2326310B1 · 2019
ລີວິວ
ຍັງບໍ່ມີລີວິວ. ເຄີຍເຮັດວຽກກັບ Assertio Therapeutics, Inc. ບໍ? ເປັນຄົນທຳອິດທີ່ແບ່ງປັນປະສົບການ.
ຂໍ້ມູນທາງກົດໝາຍ
| ຊື່ທາງກົດໝາຍ | Assertio Therapeutics, Inc. |
|---|---|
| LEI | 549300L2A9NTF1JVDP20ເບິ່ງໃນ GLEIF ↗ |
| ທີ່ຢູ່ທີ່ລົງທະບຽນ | 251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US |
| ສະຖານະ | ໃຊ້ງານຢູ່ |
ແຫຼ່ງຂໍ້ມູນ: GLEIF · ອັບເດດ Oct. 16, 2026
ຕິດຕໍ່ ແລະ ລິ້ງ
ສະຖານທີ່
251 LITTLE FALLS DRIVE, 19808, WILMINGTON, US
ນີ້ແມ່ນບໍລິສັດຂອງທ່ານບໍ?
ອ້າງສິດໜ້ານີ້ຟຣີເພື່ອເພີ່ມໂລໂກ້, ຜະລິດຕະພັນ, ຮູບ ແລະ ວຽກ, ແລະ ເພື່ອຕອບລີວິວ.
ອ້າງສິດໜ້ານີ້ເຂົ້າຮ່ວມ Heelky ເພື່ອເຊື່ອມຕໍ່, ຈ້າງ ແລະ ເຕີບໂຕ
ສ້າງບັນຊີຟຣີເພື່ອສົ່ງຂໍ້ຄວາມຫາຄົນ, ສະໝັກວຽກ ແລະ ໂພສພາລະກິດ.
ເຂົ້າຮ່ວມດຽວນີ້ — ຟຣີ